Halozyme Says CHMP Recommends Approval Of Subcutaneous Rybrevant Developed With ENHANZE In NSCLC

(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company, received European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommendation for extension of marketing authorisation for a subcutaneous formulation of Rybrevant in combination with Lazcluze, Halozyme Therapeutics, Inc. (HALO) said in a statement on Monday. This formuation is used for the treatment of advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC).

Rybrevant has been developed with Halozyme's ENHANZE drug delivery technology.

The CHMP positive opinion is supported by positive results from the Phase 3 PALOMA-3 study.